Related Experiment Video
Updated: Jan 16, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Comparison of Collagen Cross-Linking Alone to 1% Povidone-Iodine Treatment of Refractory Corneal Ulcers: A Randomized
Mohammad-Hosein Validad1, Soroush Jamshidian1, Tahereh Rakhshandadi2
1Department of Ophthalmology, Alzahra Eye Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.
Abstract:
Background: Corneal ulcer is one of the most common causes of corneal opacities. This study compared the effects of topical 1% povidone-iodine (PI) and corneal collagen cross-linking in patients with therapy-resistant corneal ulcers. Methods: This single-blind randomized clinical trial included patients referred to Al-Zahra Ophthalmology Hospital in Zahedan, Iran, from 2022 to 2024, who had corneal ulcers resistant to standard therapy. Participants were divided into two groups using stratified permuted block randomization method: one group received 1% PI and the other underwent corneal collagen cross-linking. Signs and symptoms were recorded before treatment and on days 1, 3, 7, and 28 posttreatment. Statistical analysis was performed using generalized estimating equations and repeated measures analysis of variance (ANOVA). Results: Thirty patients, with a mean age of 52.23 ± 2.34 years, participated in this study. Both corneal collagen cross-linking and 1% PI treatments significantly reduced the wound area, stromal infiltration, hypopyon, corneal edema, eye itching, eye burning, and eye pain (p < 0.05). However, no statistically significant differences were observed between the two treatments (p > 0.09). The improvement rate was 73.3% in the 1% PI group and 60% in the corneal collagen cross-linking group. Conclusions: Corneal collagen cross-linking and 1% PI demonstrated comparable efficacy in promoting healing of refractory corneal ulcers. Therefore, both methods may be considered for managing corneal ulcers that are resistant to standard therapy. Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20221230056988N1.
More Related Videos
12:25Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018
05:56Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Related Concept Videos
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Ulcerative Colitis in IBD